Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study
(2011) Anticancer Research : international journal of cancer research and treatment — Vol. 31, n° 4, p. 1407-1409 (2011)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- AIM: To determine imatinib nonadherence rates in patients with gastrointestinal tumors (GIST) over 90 days. PATIENTS AND METHODS: A prospective 90-day observational, open-label, multicenter study was carried out of 28 evaluable GIST patients on imatinib. Nonadherence behavior was measured using a 4-item patient interview. Clinicians, patients, and collaterals rated perceived patient adherence on a 0-100 VAS scale. RESULTS: Nonadherence rates in the 4 weeks prior to baseline and follow-up were 29% (95% CI=26-32) and 24% (95% CI=21-27, p>0.05). Mean VAS ratings of perceived adherence ranged from 95.2 ± 10.2 to 97.3 ± 4.8 (p>0.05 for time and source of rating). Correlations between perceptions of and actual adherence behavior were negative. CONCLUSION: In this first study on imatinib nonadherence in GIST patients, rates were similar to those observed in patients with chronic myeloid leukemia, higher than clinically expected and exceeding meta-analytic estimates for cancer. Nonadherence rates were consistent across the 90-day period. Nonadherence behavior should be assessed by clinicians.
- Affiliations
Citations
Mazzeo, F., Duck, L., Joosens, E., Dirix, L., Focan, C., Forget, F., De Geest, S., Muermans, K., VAN Lierde, M.-A., Macdonald, K., Abraham, I., & De Grève, J. (2011). Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Research : international journal of cancer research and treatment, 31(4), 1407-1409. https://hdl.handle.net/2078.5/68490 (Original work published 2011)